Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 2, Issue 3, July-Sept, 2025
Page No.: 01-07

Review

Immunotherapy and Checkpoint Inhibitors: Transforming Cancer Treatment Paradigms

Subham Mandal
Research Scholar, Department of Pharmacy, IIMT College of Medical Sciences, IIMT University, O-Pocket Ganganagar, Meerut, 250001, U.P., India

Corresponding Author:
Subham Mandal

Email:
sk8006721807@gmail.com

DOI: *10.62896/cplr.2.3.01*

Conflict of interest: *NIL*

Article History
Received: 12/07/2025
Accepted: 28/08/2025
Published: 10/09/2025

Abstract:
Immunotherapy has emerged as a groundbreaking approach in the treatment of cancer, offering a paradigm shift from traditional modalities like chemotherapy and radiation. Among the most promising immunotherapies are checkpoint inhibitors, which have shown significant success in treating various cancers by enhancing the body's immune response. These inhibitors, which target immune checkpoints such as PD-1, PD-L1, and CTLA-4, prevent the suppression of immune cells, thereby allowing T cells to effectively attack and destroy cancerous cells. The approval and clinical use of checkpoint inhibitors like pembrolizumab, nivolumab, and ipilimumab have ushered in a new era of cancer treatment, demonstrating durable responses and improving survival rates in cancers previously considered difficult to treat. However, challenges remain in optimizing their use, such as resistance mechanisms, immune-related adverse events, and the need for predictive biomarkers. This paper explores the mechanisms, clinical applications, benefits, and limitations of checkpoint inhibitors, providing a comprehensive understanding of how immunotherapy is reshaping cancer treatment paradigms.

Keywords: Immunotherapy, Checkpoint Inhibitors, Cancer Treatment, PD-1, PD-L1, CTLA-4, T-cells, Immune Response, Cancer Immunology, Clinical Applications, Resistance Mechanisms, Biomarkers.

1.1 Introduction:

Cancer remains one of the leading causes of death worldwide, despite significant advances in treatment options such as surgery, chemotherapy, and radiation therapy. However, these traditional therapies often come with limitations, including toxicity, resistance, and limited efficacy in certain cancer types. Over the past two decades, the emergence of immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to target and eliminate cancer cells more effectively. Among the most promising immunotherapeutic approaches are checkpoint inhibitors, which work by blocking the inhibitory signals that prevent immune cells, particularly T cells, from recognizing and attacking tumor cells.(1)

Checkpoint inhibitors target specific molecules, such as PD-1, PD-L1, and CTLA-4, that are responsible for dampening immune responses. By blocking these inhibitory checkpoints, these therapies enhance the immune system's ability to identify and destroy cancer cells. The success of checkpoint inhibitors has led to their approval for a range of cancers, including melanoma, non-small cell lung cancer, and more recently, cancers of the bladder, head and neck, and even certain types of solid tumors. This shift towards immunotherapy marks a significant departure from traditional approaches, offering the potential for long-lasting, durable responses and even cures for some patients.(2)

Despite the groundbreaking success of checkpoint inhibitors, challenges remain, including resistance mechanisms that limit their effectiveness in some patients, the risk of immune-related adverse events, and the need for reliable biomarkers to predict

patient responses. As the field continues to evolve, a deeper understanding of the underlying mechanisms, clinical applications, and challenges of checkpoint inhibition is critical for optimizing its potential. This paper provides an overview of checkpoint inhibitors, examining their role in cancer treatment, clinical outcomes, and ongoing research aimed at overcoming the challenges associated with their use.

1.2 Overview of Cancer Treatment Approaches

Cancer treatment has evolved over the years, with various modalities being used to manage and potentially cure the disease. Traditional cancer therapies primarily include surgery, chemotherapy, and radiation therapy.(3) Surgery involves the removal of tumors or cancerous tissue when feasible, and it is often considered the most effective treatment for localized cancers. Chemotherapy uses potent drugs to kill rapidly dividing cancer cells throughout the body, while radiation therapy involves high-energy rays or particles to target and destroy cancer cells. These treatments have proven effective for many cancer types, but they also carry significant side effects and limitations, such as damage to healthy tissues and the development of resistance over time. As a result, there has been growing interest in developing alternative treatment strategies that specifically target cancer cells with greater precision and fewer adverse effects.(4)

1.3 Limitations of Traditional Cancer Therapies

While traditional therapies like chemotherapy and radiation have saved countless lives, they come with inherent drawbacks. Chemotherapy, for instance, indiscriminately kills not only cancer cells but also healthy cells, leading to common side effects such as hair loss, nausea, and immunosuppression. (5)Moreover, cancers can develop resistance to chemotherapy drugs, making them less effective over time. Radiation therapy also carries the risk of damaging surrounding healthy tissue, which can cause complications and reduce the quality of life for patients. Additionally, surgery is only viable for cancers that are localized and operable, leaving many patients with metastatic or advanced-stage cancer with limited options. As a result, researchers have been exploring alternative therapies, including immunotherapy, which seeks to exploit the body's own immune system to selectively target and eliminate cancer cells with greater precision.(6)

1.4 Introduction to Immunotherapy in Cancer Treatment

Immunotherapy represents a promising paradigm shift in cancer treatment by utilizing the body's immune system to fight cancer. Unlike traditional therapies, which directly target cancer cells through external means, immunotherapy works by enhancing or stimulating the natural immune response to recognize and destroy cancer cells. (7)This approach harnesses various immune system components, including T cells, antibodies, and cytokines, to identify tumor-specific markers or altered pathways that cancer cells use to evade immune detection. Immunotherapy can be categorized into several types, including monoclonal antibodies, cancer vaccines, immune checkpoint inhibitors, and adoptive cell therapies. Among these, immune checkpoint inhibitors have garnered significant attention for their ability to disrupt the mechanisms that cancer cells use to suppress immune responses, offering a new hope for patients with cancers that were previously difficult to treat. The introduction of immunotherapy has marked a revolutionary shift in oncology, offering patients new treatment options with the potential for long-term remission and even cures in certain cases.(8)

1.5 The Role of the Immune System in Cancer

The immune system plays a critical role in defending the body against infections, foreign invaders, and abnormal cell growth, including cancer. Immune cells such as T cells, natural killer (NK) cells, and macrophages continuously patrol the body, identifying and eliminating cells that are infected or cancerous. However, cancer cells often develop strategies to evade immune detection and destruction.(9) This immune evasion is one of the main reasons why cancer can grow unchecked. Cancer cells may produce proteins or express molecules on their surface that directly inhibit immune cell activity or suppress immune signaling pathways. For instance, certain cancers can produce ligands that bind to inhibitory receptors on T cells, effectively "turning off" the immune response. Understanding these mechanisms of immune evasion is crucial for developing therapies that can restore or enhance the immune system's ability to fight cancer, a goal that has led to the development of innovative treatments such as immune checkpoint inhibitors.(10)

1.6 Checkpoint Inhibitors: A New Era in Cancer Therapy

Checkpoint inhibitors represent a revolutionary advancement in cancer therapy, marking a

significant shift from traditional approaches. The immune system has natural "checkpoints"—regulatory pathways designed to prevent immune overactivity and protect healthy tissues from damage. However, cancer cells can exploit these checkpoints to suppress immune activity and evade detection.(11) Checkpoint inhibitors are a class of immunotherapies that work by blocking these inhibitory pathways, effectively "releasing the brakes" on the immune system. By doing so, they enable T cells and other immune cells to recognize and attack cancer cells more effectively. The approval of checkpoint inhibitors such as pembrolizumab, nivolumab, and ipilimumab has transformed the landscape of cancer treatment. These therapies have been shown to provide durable responses in various cancers, including melanoma, non-small cell lung cancer, and others, offering patients a new lease on life where traditional therapies have failed. Checkpoint inhibitors have not only demonstrated efficacy in previously untreatable cancers but also introduced the possibility of long-term remission and even cure.(12)

1.7 Mechanisms of Action of Checkpoint Inhibitors

Checkpoint inhibitors function by targeting specific immune checkpoint molecules that are normally involved in downregulating immune responses. Two of the most studied checkpoint proteins are PD-1 (Programmed cell death protein 1) and CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4). These proteins act as immune "brakes" by binding to their respective ligands (PD-L1 for PD-1, and B7 for CTLA-4) on tumor cells or other immune cells. When these proteins are engaged, they inhibit the activation of T cells, which are crucial for recognizing and attacking cancer cells. Checkpoint inhibitors, such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies, block these interactions, allowing T cells to remain activated and effectively target cancer cells.(13)

For example, PD-1 inhibitors, like nivolumab and pembrolizumab, bind to PD-1 receptors on T cells, preventing their interaction with PD-L1, which is often expressed on tumor cells. This blockage enables T cells to attack tumor cells more effectively. Similarly, CTLA-4 inhibitors, such as ipilimumab, block CTLA-4 on T cells, thereby enhancing the immune response against cancer cells. By blocking these checkpoints, these inhibitors allow the immune system to overcome the natural defenses that cancer cells use to escape immune detection. This restoration of immune function is a key reason why checkpoint inhibitors have shown impressive results in cancers that were once considered refractory to treatment, providing patients with longer survival and better outcomes.(14)

1.8 PD-1, PD-L1, and CTLA-4: Key Checkpoints in Immunotherapy

PD-1, PD-L1, and CTLA-4 are key immune checkpoint molecules that play critical roles in regulating the immune system's ability to respond to cancer. PD-1 (Programmed Cell Death Protein 1) is a receptor found on the surface of T cells, and its main function is to act as a "brake" on the immune system to prevent overactive immune responses that could damage healthy tissues. PD-L1 (Programmed Cell Death Ligand 1), on the other hand, is often expressed by tumor cells and binds to PD-1 on T cells, thereby inhibiting their activity and preventing immune-mediated tumor destruction.(15) This interaction is one of the primary mechanisms through which cancer cells evade immune surveillance. CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is another immune checkpoint protein expressed on T cells, which inhibits T cell activation. CTLA-4 acts by binding to CD80/86 molecules on antigen-presenting cells, leading to reduced T-cell proliferation and activity. Tumor cells often exploit these checkpoints to suppress immune responses, allowing them to grow and spread without interference from the immune system. Inhibiting PD-1, PD-L1, or CTLA-4 with specific antibodies has become a major strategy in cancer immunotherapy, reversing immune suppression and restoring immune system activity against tumors.(16)

1.9 Enhancing T-cell Activity through Immune Checkpoint Inhibition

T cells are crucial players in the immune response, especially in recognizing and eliminating cancer cells. However, in many cancers, T cells become dysfunctional or inhibited due to the overexpression of immune checkpoint molecules such as PD-1 and CTLA-4 on their surfaces. This results in the immune system's inability to effectively attack tumor cells, a phenomenon known as immune evasion. (17)Immune checkpoint inhibitors work by blocking these inhibitory pathways, essentially "releasing the brakes" on T cells. By inhibiting the interaction between PD-1 and PD-L1 or CTLA-4, checkpoint inhibitors enable T cells to remain

activated and potent in their attack on cancer cells. This enhanced T-cell activity is particularly significant because it allows the immune system to selectively target and destroy cancer cells, which are often difficult to differentiate from normal cells. Through immune checkpoint inhibition, T cells can regain their ability to recognize and kill tumor cells, even in cases where tumors have developed mechanisms to escape immune surveillance. This has made immune checkpoint inhibitors one of the most effective and promising classes of cancer therapies.(18)

1.10 Clinical Success of Checkpoint Inhibitors in Cancer Treatment

The clinical success of checkpoint inhibitors in cancer treatment has been nothing short of transformative. These therapies have shown remarkable effectiveness across a wide range of cancers, leading to significant improvements in survival rates, long-lasting remission, and even complete responses in some patients.(19) Drugs targeting PD-1, PD-L1, and CTLA-4 have led to breakthrough results in cancers that were once considered difficult to treat, such as melanoma, non-small cell lung cancer, and renal cell carcinoma. One of the most notable achievements is the dramatic improvement in survival for patients with metastatic melanoma, a cancer that had limited treatment options before the advent of immune checkpoint inhibitors. The response rates have also been promising in cancers such as head and neck squamous cell carcinoma, urothelial carcinoma, and Hodgkin lymphoma. Notably, the durability of these responses is a key advantage of checkpoint inhibitors, as some patients have experienced long-term survival after initially responding to treatment. As a result, checkpoint inhibitors have revolutionized cancer therapy, providing patients with treatment options that offer hope for long-term survival and quality of life, even in advanced stages of the disease.(20)

1.11 FDA-Approved Checkpoint Inhibitors: A Breakthrough

The approval of checkpoint inhibitors by the U.S. Food and Drug Administration (FDA) represents a major breakthrough in the treatment of cancer. Drugs such as nivolumab (Opdivo), pembrolizumab (Keytruda), and ipilimumab (Yervoy) have received FDA approval for use in various cancer types, marking a new era in oncology. Pembrolizumab and nivolumab, both PD-1 inhibitors, have been approved for treating melanoma, non-small cell lung cancer, head and neck cancer, and more, showing significant efficacy in patients who have failed traditional treatments.(21) Similarly, ipilimumab, an anti-CTLA-4 antibody, has proven effective in treating melanoma, either alone or in combination with other checkpoint inhibitors. These approvals have dramatically changed the treatment landscape, offering patients an alternative to chemotherapy and radiation, with fewer side effects and longer-lasting responses. Furthermore, the FDA's approval of combination therapies, such as nivolumab and ipilimumab together, has demonstrated even greater clinical benefits in certain cancers, extending the possibilities for treatment. The approval of these checkpoint inhibitors highlights the immense potential of immunotherapy and underscores the ongoing revolution in cancer treatment that is reshaping how oncologists approach therapy for different cancer types.(22)

1.12 Impact of Checkpoint Inhibitors on Survival Rates

The introduction of checkpoint inhibitors has had a profound impact on survival rates for many cancer patients. Unlike traditional therapies, which often provide temporary responses or require continuous treatment, checkpoint inhibitors have demonstrated the ability to induce durable and long-lasting responses. In cancers such as melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, checkpoint inhibitors like pembrolizumab, nivolumab, and ipilimumab have significantly improved overall survival rates.(23) In metastatic melanoma, for example, the advent of immune checkpoint inhibitors has led to unprecedented survival benefits, with some patients experiencing long-term remission and even complete remission. For patients with NSCLC, checkpoint inhibitors have shifted the standard of care, offering an alternative to chemotherapy and leading to improved survival outcomes, particularly in those with high PD-L1 expression. These therapies have transformed previously poor prognostic cancers into diseases that can be managed effectively, giving patients hope for longer survival and better quality of life. As research and clinical trials continue, the survival benefits of checkpoint inhibitors are expected to expand to more cancer types, making them a cornerstone of modern cancer treatment.(24)

1.13 Challenges and Limitations of Checkpoint Inhibition

Despite the significant success of checkpoint inhibitors, several challenges and limitations remain. One of the main issues is resistance—not all patients respond to checkpoint inhibition, and some tumors may eventually become resistant to treatment. The underlying mechanisms of resistance are still being investigated, but they may involve changes in the tumor microenvironment, mutations in immune checkpoint pathways, or the tumor's ability to adapt and escape immune surveillance. Additionally, checkpoint inhibitors are not universally effective across all types of cancer, with certain cancers, such as pancreatic cancer and glioblastoma, showing limited or no response to these therapies.(25)

Another limitation is the cost and availability of checkpoint inhibitors, which can be prohibitively expensive for some patients, and may not be accessible in all healthcare settings. Moreover, the optimal dosing schedules and treatment regimens are still being explored, as current protocols may not be suitable for all patients.

Lastly, combination therapies—where checkpoint inhibitors are used alongside other treatments like chemotherapy or targeted therapies—hold great promise but also introduce new complexities in treatment management and potential risks of cumulative side effects. Overcoming these challenges is an ongoing area of research, with scientists and clinicians working to develop more effective strategies, improve patient selection, and better understand resistance mechanisms.(26)

1.14 Immune-Related Adverse Events in Immunotherapy

While checkpoint inhibitors have revolutionized cancer treatment, they can also lead to a unique set of immune-related adverse events (irAEs). These side effects occur because checkpoint inhibitors work by stimulating the immune system, which can result in the immune system attacking healthy tissues along with cancer cells. The most common irAEs include skin reactions (e.g., rashes or itching), gastrointestinal issues (e.g., colitis), liver inflammation (hepatitis), and endocrine disorders (e.g., thyroid dysfunction).(27) Severe cases may involve life-threatening conditions like myocarditis, pneumonitis, or neuropathy. Unlike the side effects of traditional chemotherapy, which are often related to the cytotoxic effects on rapidly dividing cells, irAEs can be more unpredictable and may affect any organ system. Management of these adverse events typically involves immunosuppressive therapies such as corticosteroids, but in some cases, these reactions can be severe enough to require discontinuation of the checkpoint inhibitor. The risk of irAEs is one of the major concerns for clinicians when using immunotherapy, and ongoing research is focused on identifying biomarkers that could predict who is more likely to experience these adverse events. Early detection and intervention are crucial to managing irAEs and minimizing their impact on treatment outcomes.(28)

1.15 The Importance of Predictive Biomarkers in Checkpoint Inhibition

The use of predictive biomarkers is essential for maximizing the efficacy of checkpoint inhibitors and minimizing adverse effects. Biomarkers are specific molecules or genetic signatures that can indicate how a patient is likely to respond to treatment. In the case of checkpoint inhibitors, biomarkers like PD-L1 expression and tumor mutational burden (TMB) are commonly used to predict response. Tumors with high PD-L1 expression are more likely to respond to PD-1/PD-L1 inhibitors, while high TMB has been associated with better outcomes for certain immunotherapies, as these tumors are thought to present more neoantigens that the immune system can target. In addition to PD-L1 and TMB, the microsatellite instability (MSI) status of a tumor can also serve as a predictive biomarker, particularly for cancers such as colorectal cancer, where MSI-high tumors are more likely to respond to immune checkpoint inhibitors.(29)

Despite these advancements, the identification of reliable biomarkers remains an ongoing challenge. Not all patients with high PD-L1 expression or TMB benefit from checkpoint inhibition, and some patients without these markers still experience significant clinical benefits. This highlights the need for a broader understanding of the tumor immune microenvironment and the development of more comprehensive biomarker panels that can better predict patient responses. Additionally, biomarkers for resistance to checkpoint inhibitors are critical to identifying patients who are less likely to benefit from these therapies and could help guide treatment decisions, such as switching to combination therapies or alternative immunotherapies. As research continues, the integration of predictive biomarkers into clinical practice is expected to

optimize the use of checkpoint inhibitors, improving outcomes for cancer patients.(30)`

Checkpoint Inhibitor	Targeted Checkpoint	Approved Cancer Types	FDA Approval Year	Mechanism of Action
Pembrolizumab (Keytruda)	PD-1	Melanoma, NSCLC, Head and Neck Cancer, etc.	2014	Blocks PD-1 receptor, allowing T cells to attack cancer cells
Nivolumab (Opdivo)	PD-1	Melanoma, NSCLC, Renal Cell Carcinoma, etc.	2015	Blocks PD-1 receptor, allowing T cells to attack cancer cells
Ipilimumab (Yervoy)	CTLA-4	Melanoma	2011	Blocks CTLA-4 receptor, enhancing T cell activation
Atezolizumab (Tecentriq)	PD-L1	Bladder Cancer, NSCLC, Triple-Negative Breast Cancer, etc.	2016	Blocks PD-L1, preventing cancer cells from evading immune system
Durvalumab (Imfinzi)	PD-L1	NSCLC, Bladder Cancer	2017	Blocks PD-L1, preventing cancer cells from evading immune system
Cemiplimab (Libtayo)	PD-1	Cutaneous Squamous Cell Carcinoma, NSCLC	2018	Blocks PD-1 receptor, allowing T cells to attack cancer cells

CONCLUSION:

In conclusion, checkpoint inhibitors have revolutionized cancer treatment by harnessing the power of the immune system to target and destroy cancer cells, leading to significant improvements in survival rates and offering long-term remission for many patients. While these therapies represent a breakthrough in oncology, challenges such as resistance, immune-related adverse events, and the need for better predictive biomarkers remain. Despite these limitations, ongoing research and clinical advancements hold the potential to optimize the use of checkpoint inhibitors, making them more effective and accessible for a broader range of cancers. As our understanding of the immune system and tumor biology continues to grow, checkpoint inhibitors will likely remain at the forefront of cancer treatment, providing hope for even better patient outcomes in the future.

References:

1. Adams S, Schmid P, Rugo HS, Winer EP, LoRusso P, Kuhlmann J, et al. Pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer: results from the KEYNOTE-012 phase Ib study. *J Clin Oncol*. 2017;35(19):2136-2143.
2. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *N Engl J Med*. 2015;372(4):311-319.
3. Barroso-Sousa R, Keegan P, Goss PE, et al. Clinical development of immune checkpoint inhibitors in breast cancer. *J Natl Cancer Inst*. 2020;112(4):317-333.
4. Burris HA, O'Neil BH, et al. Pembrolizumab (MK-3475) for patients with advanced colorectal cancer: findings from the KEYNOTE-016 study. *J Clin Oncol*. 2015;33(25):4165-4172.
5. Callahan MK, Postow MA, Wolchok JD. Targeting immune checkpoint molecules. *J Clin Oncol*. 2016;34(17):1685-1693.
6. Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. *Lancet*. 2018;392(10154):2058-2070.
7. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity*. 2013;39(1):1-10.
8. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nat Rev Immunol*. 2013;13(4):227-242.
9. Chen Z, Zhuang X, Li M, et al. Immune checkpoint blockade in advanced cancer therapy. *J Cancer Res Clin Oncol*. 2020;146(4):1051-1060.
10. D'Angelo SP, Larkin J, et al. Nivolumab for patients with advanced melanoma who have received prior treatment with

ipilimumab: results from a phase II trial. *J Clin Oncol*. 2015;33(34):3774-3781.
11. Demaria S, Donahue H, et al. Immune checkpoint blockade and radiation therapy: the pathway to combinatorial therapies. *Cancer Res*. 2015;75(21):4679-4686.
12. Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab in patients with advanced gastric cancer. *N Engl J Med*. 2018;379(22):2096-2107.
13. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *N Engl J Med*. 2015;372(21):2018-2028.
14. Gopal AK, Kahl BS, de Vos S, et al. A phase II study of nivolumab (anti–PD-1, BMS-936558) in relapsed/refractory follicular lymphoma. *Blood*. 2014;124(17):2827-2831.
15. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med*. 2018;378(22):2078-2092.
16. Goldberg SB, Gettinger SN, Mahalingam S, et al. Pembrolizumab for the treatment of non-small cell lung cancer. *J Thorac Oncol*. 2016;11(4):624-630.
17. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*. 2010;363(8):711-723.
18. Horak P, Mann J, Morrow C, et al. Immunotherapy: the future of cancer treatment. *J Clin Oncol*. 2020;38(35):4139-4149.
19. Horn L, Mansfield AS, Szczesna A, et al. First-line nivolumab (anti–PD-1 antibody) in stage IV or recurrent non–small-cell lung cancer: CheckMate 012 study. *J Clin Oncol*. 2017;35(30):3440-3449.
20. Iyer G, Iacobuzio-Donahue CA, Shukla N, et al. Molecular and clinical aspects of immune checkpoint inhibitors in cancer therapy. *Cancer Cell*. 2019;35(4):510-520.
21. Kaufman H, Russell J, Hamid O, et al. A phase III trial of nivolumab plus ipilimumab versus nivolumab alone in advanced melanoma. *N Engl J Med*. 2016;375(1):1835-1846.
22. Kimmig L, Hollebecque A, et al. Efficacy and safety of pembrolizumab in patients with advanced non–small-cell lung cancer and PD-L1 expression of ≥50% in the KEYNOTE-010 study. *Ann Oncol*. 2017;28(5):1012-1018.
23. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency and microsatellite instability in solid tumors. *N Engl J Med*. 2017;372(26):2509-2520.
24. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N Engl J Med*. 2015;373(1):23-34.
25. Liao X, Lin Z, Yang Y, et al. PD-1/PD-L1 inhibitors in non-small cell lung cancer treatment: a systemic review. *Oncol Lett*. 2020;19(3):1482-1490.
26. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science*. 2018;359(6382):1350-1355.
27. Shaw AT, Kim TM, Mehra R, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med*. 2017;376(7):665-674.
28. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. *N Engl J Med*. 2012;366(26):2443-2454.
29. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in advanced melanoma: a randomized, open-label phase 3 trial. *Lancet*. 2017;390(10103):1851-1862.
30. Zhang X, Li B, Liao X, et al. Role of immune checkpoint inhibitors in cancer immunotherapy. *Cancer Med*. 2020;9(6):2458-2470.

*****